Home › Disorders of Excessive Somnolence
Disorders of Excessive Somnolence clinical trials recruiting in the U.S.
15 studies for Disorders of Excessive Somnolence are recruiting participants at sites across the United States.
Cities with the most studies
- Atlanta, GA9 studies
- San Antonio, TX9 studies
- Cincinnati, OH9 studies
- Charlotte, NC8 studies
- Miami, FL8 studies
- Orlando, FL7 studies
- Austin, TX7 studies
- Columbia, SC7 studies
- Sugar Land, TX7 studies
- Brandon, FL6 studies
- Los Angeles, CA5 studies
- Reading, PA5 studies
- Macon, GA5 studies
- Lansing, MI5 studies
- Baltimore, MD4 studies
- Philadelphia, PA4 studies
- Houston, TX4 studies
- Farmington Hills, MI4 studies
- Boulder, CO4 studies
- Staten Island, NY4 studies
- Colorado Springs, CO4 studies
- Dallas, TX4 studies
- Brooklyn, NY3 studies
- Chicago, IL3 studies
- Phoenix, AZ3 studies
- Madison, WI3 studies
- St. Louis, MO3 studies
- Kansas City, KS3 studies
- Columbus, OH3 studies
- Sterling Heights, MI3 studies
By state
- Alabama7 studies
- Arizona6 studies
- California8 studies
- Colorado7 studies
- Florida9 studies
- Georgia10 studies
- Illinois4 studies
- Kansas3 studies
- Maryland4 studies
- Massachusetts4 studies
- Michigan7 studies
- Missouri4 studies
- Nevada3 studies
- New Jersey5 studies
- New York4 studies
- North Carolina9 studies
- Ohio10 studies
- Pennsylvania6 studies
- South Carolina9 studies
- Texas10 studies
- Wisconsin4 studies
Recently updated studies
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
RecruitingPhase 2/3
Ages 18 to 70 · All sexes · Updated Oct 2, 2026 · NCT07598708A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07500090A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 3, 2026 · NCT07455383A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 3, 2026 · NCT07502443A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07540364A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 3, 2026 · NCT07540897A Study of Pitolisant in Patients With Prader-Willi Syndrome
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Aug 25, 2026 · NCT06366464A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
RecruitingPhase 2/3
Ages 18 to 70 · All sexes · Updated Aug 7, 2026 · NCT06767683Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT06568367Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Jun 9, 2026 · NCT06170970Impact of Bright Light Therapy on Prader-Willi Syndrome
Recruiting
Ages 6 to 88 · All sexes · Updated May 15, 2026 · NCT05939453A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Apr 16, 2026 · NCT07096674A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 80 · All sexes · Updated Dec 24, 2025 · NCT07082829Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
RecruitingObservational study
All ages · All sexes · Updated May 29, 2025 · NCT01793168From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.